Page last updated: 2024-12-06

caracemide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID54747
CHEMBL ID9116
SCHEMBL ID3812
MeSH IDM0129860

Synonyms (45)

Synonym
caracemide
NSC253272 ,
81424-67-1
acetamide, n-[(methylamino)carbonyl]-n-[[(methylamino)carbonyl]oxy]-
nsc-253272
NCI60_002035
NCIMECH_000225
n-acetyl-n-(methylcarbamoyloxy)-n'-methylurea
brn 5935912
caracemidum [latin]
c6h11n3o4
n-(methylcarbamoyl)-n-(methylcarbamoyloxy)acetamid
acetamide, n-((methylamino)carbonyl)-n-((methylamino)carbonyl)oxy)-
caracemida [spanish]
nsc 253272
n-acetyl-n,o-bis(methylcarbamoyl)hydroxylamine
caracemide [usan:inn]
acetamide, n-((methylamino)carbonyl)-n-(((methylamino)carbonyl)oxy)-
acetamide, n-((methylamino)carbonyl)-n-((methylamino)carbonyl)oxy-
ccris 1729
n-((methylamino)carbonyl)-n-(((methylamino)carbonyl)oxy)acetamide
D03378
caracemide (usan)
CHEMBL9116
[acetyl(methylcarbamoyl)amino] n-methylcarbamate
AKOS006274247
caracemida
h74f6j185a ,
caracemidum
unii-h74f6j185a
CCG-35357
caracemide [usan]
caracemide [mart.]
caracemide [inn]
SCHEMBL3812
DTXSID00231099
1-([(methylamino)carbonyl]([(methylamino)carbonyl]oxy)amino)-1-oxoethane #
n-(methylcarbamoyl)acetamido n-methylcarbamate
Z1198155457
CS-0078854
HY-119974
n-(methylcarbamoyl)-n-((methylcarbamoyl)oxy)acetamide
Q27279722
MS-23021
EN300-255559

Research Excerpts

Actions

Caracemide did not inhibit basal adenylate cyclase activity in either intact cells or homogenates. It inhibited adenyllatecyclase activated by prostaglandin E1 (PGE1) or forskolin. Caracemid was found to inhibit choline acetyltransferase (CAT) from rat brain.

ExcerptReferenceRelevance
"Caracemide did not inhibit basal adenylate cyclase activity in either intact cells or homogenates, but inhibited adenylate cyclase activated by prostaglandin E1 (PGE1) or forskolin."( Effect of the antitumor drug caracemide on the neurochemistry of murine neuroblastoma cells (clone N1E-115).
McKinney, M; Pfenning, M; Richelson, E, 1986
)
1.28
"Caracemide was found to inhibit choline acetyltransferase (CAT) from rat brain. "( The effect of the experimental antitumor agent caracemide on brain choline acetyltransferase.
Farquhar, D; Feiffer, R; Fields, WS; Ho, BT; Krakoff, IH; Newman, RA; Tansey, LW, 1988
)
1.97

Compound-Compound Interactions

ExcerptReferenceRelevance
" Hydroxyurea, 2,2'-bipyridine and 1,10-phenanthroline combined with caracemide synergistically inhibited DNA synthesis, while Desferal did not show any such effect."( In vitro cytotoxicity of caracemide alone and in combination with hydroxyurea or iron-chelating agents in human chronic myeloid leukemia cells and murine tumors.
Advani, SH; Chitnis, MP; Satyamoorthy, K, 1988
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)10.00000.00403.43889.5100AID1640022
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)1.33000.00022.45859.9600AID1640021
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID122379Antitumor activity was evaluated for the compound against the M5076 reticulum cell sarcoma in mice and the % T/C(treated/control) value was calculated at optimal dose of 50 mg/kg1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID110150Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice measured as Control tumor volume for the treated at the optimal dose 50 mg/Kg/day1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
AID116884Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice at dose of 150-6.25 mg/kg per day1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
AID116700Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice at dose of 150-6.25 mg/kg per day1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
AID118810Antitumor activity was evaluated against the M5076 reticulum cell sarcoma in mice measured as mean tumor volume for the treated at the optimal dose 50 mg/Kg/day1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (65.00)18.7374
1990's5 (25.00)18.2507
2000's1 (5.00)29.6817
2010's1 (5.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.98 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (19.05%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (80.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]